| Name | Title | Contact Details |
|---|
Developed by spine specialists, the SpineZone Method relieves long-term back and neck injuries without resorting to surgery.
Serving Southeastern Wisconsin since 1974, Home Care Medical, Inc. provides home infusion, enteral nutrition and hospice care; rehab technology; respiratory care; home medical equipment and supplies; and bracing and compression garments. In addition to the Corporate Headquarters located at 5665 South Westridge Drive in New Berlin, Wisconsin, Home Care Medical, Inc. has three retail store locations at 4818 South 76th Street in Milwaukee, Wisconsin; 2922 South Business Drive in Sheboygan, Wisconsin; and 1709 South 18th Avenue in West Bend, Wisconsin. Home Care Medical, Inc. is the WAMES (Wisconsin Association of Medical Equipment Services) HME Provider of the Year award recipient in 2013 and 2012. Accredited by the Joint Commission and an active member of WAMES, the MedGroup and AAHomecare, Home Care Medical’s mission is to enhance the lives of those we serve.
Wherever you are, exhale Therapeutic Air® to immediately access the ancient wellness art of aromatherapy. Unlike topical oils or household diffusers, MONQ® is enhanced for convenience in the modern age. Experience the most direct form of aromatherapy with MONQ Personal Diffuser.
The Top Fitness Boot Camp Known To Flatten Your Stomach & Tone Your Entire Body In A Safe, Fun And Non-Intimidating Atmosphere! 90% OFF 5 Week Challenge
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.